These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 21799481

  • 1. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z, Wu NN, Zhao W, Chain DC, Schaffer E, Zhang X, Yamdagni P, Palejwala VA, Fan C, Favara SG, Dressler HM, Economides KD, Weinstock D, Cavallo JS, Naimi S, Galzin AM, Guillot E, Pruniaux MP, Tocci MJ, Polites HG.
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, Jain MR.
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P.
    Behav Brain Res; 2012 Oct 01; 234(2):192-204. PubMed ID: 22771813
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. NESS06SM reduces body weight with an improved profile relative to SR141716A.
    Mastinu A, Pira M, Pinna GA, Pisu C, Casu MA, Reali R, Marcello S, Murineddu G, Lazzari P.
    Pharmacol Res; 2013 Aug 01; 74():94-108. PubMed ID: 23756200
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
    Zhang L, Lee NJ, Nguyen AD, Enriquez RF, Riepler SJ, Stehrer B, Yulyaningsih E, Lin S, Shi YC, Baldock PA, Herzog H, Sainsbury A.
    Diabetes Obes Metab; 2010 Jul 01; 12(7):591-603. PubMed ID: 20590734
    [Abstract] [Full Text] [Related]

  • 11. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
    Migrenne S, Lacombe A, Lefèvre AL, Pruniaux MP, Guillot E, Galzin AM, Magnan C.
    Am J Physiol Regul Integr Comp Physiol; 2009 Apr 01; 296(4):R929-35. PubMed ID: 19211723
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
    Hsiao WC, Shia KS, Wang YT, Yeh YN, Chang CP, Lin Y, Chen PH, Wu CH, Chao YS, Hung MS.
    Diabetes Obes Metab; 2015 May 01; 17(5):495-504. PubMed ID: 25656402
    [Abstract] [Full Text] [Related]

  • 14. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, Pénarier G, Soubrié P, Le Fur G, Galiègue S, Casellas P.
    FASEB J; 2005 Sep 01; 19(11):1567-9. PubMed ID: 16009704
    [Abstract] [Full Text] [Related]

  • 15. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN, Lockie SH, Stefanidis A, Oldfield BJ.
    Int J Obes (Lond); 2013 Feb 01; 37(2):279-87. PubMed ID: 22473329
    [Abstract] [Full Text] [Related]

  • 16. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
    Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM.
    Diabetes Obes Metab; 2005 Jan 01; 7(1):65-72. PubMed ID: 15642077
    [Abstract] [Full Text] [Related]

  • 17. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
    Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, Choi SH, Yang EK, Park KJ, Chae HW, Moon HS, Kim SH, Shin YG, Yoon SH.
    Int J Obes (Lond); 2010 Mar 01; 34(3):547-56. PubMed ID: 20029379
    [Abstract] [Full Text] [Related]

  • 18. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.
    Lim SY, Davidson SM, Yellon DM, Smith CC.
    Basic Res Cardiol; 2009 Nov 01; 104(6):781-92. PubMed ID: 19462153
    [Abstract] [Full Text] [Related]

  • 19. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ, Serrano A, Pérez-Valero V, Jagerovic N, Hernández-Folgado L, Bermúdez-Silva FJ, Macías M, Goya P, de Fonseca FR.
    J Neuroendocrinol; 2008 May 01; 20 Suppl 1():116-23. PubMed ID: 18426510
    [Abstract] [Full Text] [Related]

  • 20. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
    Lazzari P, Sanna A, Mastinu A, Cabasino S, Manca I, Pani L.
    Behav Brain Res; 2011 Mar 01; 217(2):432-8. PubMed ID: 21074566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.